- Home
- JBGS vs NVAX Comparison
JBGS vs NVAX Comparison
Compare JBGS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- NVAX
- Stock Information
- Founded
- JBGS 2016
- NVAX 1987
- Country
- JBGS United States
- NVAX United States
- Employees
- JBGS N/A
- NVAX N/A
- Industry
- JBGS Real Estate Investment Trusts
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JBGS Real Estate
- NVAX Health Care
- Exchange
- JBGS Nasdaq
- NVAX Nasdaq
- Market Cap
- JBGS 1.3B
- NVAX 1.3B
- IPO Year
- JBGS 2017
- NVAX 1995
- Fundamental
- Price
- JBGS $14.91
- NVAX $7.99
- Analyst Decision
- JBGS Sell
- NVAX Buy
- Analyst Count
- JBGS 2
- NVAX 6
- Target Price
- JBGS $16.00
- NVAX $17.83
- AVG Volume (30 Days)
- JBGS 685.2K
- NVAX 3.7M
- Earning Date
- JBGS 02-18-2025
- NVAX 02-27-2025
- Dividend Yield
- JBGS 4.69%
- NVAX N/A
- EPS Growth
- JBGS N/A
- NVAX N/A
- EPS
- JBGS N/A
- NVAX N/A
- Revenue
- JBGS $546,890,000.00
- NVAX $885,193,000.00
- Revenue This Year
- JBGS N/A
- NVAX N/A
- Revenue Next Year
- JBGS N/A
- NVAX N/A
- P/E Ratio
- JBGS N/A
- NVAX N/A
- Revenue Growth
- JBGS N/A
- NVAX N/A
- 52 Week Low
- JBGS $13.65
- NVAX $3.81
- 52 Week High
- JBGS $18.86
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- JBGS 45.89
- NVAX 42.04
- Support Level
- JBGS $14.36
- NVAX $7.70
- Resistance Level
- JBGS $15.69
- NVAX $8.54
- Average True Range (ATR)
- JBGS 0.39
- NVAX 0.39
- MACD
- JBGS -0.01
- NVAX -0.04
- Stochastic Oscillator
- JBGS 41.35
- NVAX 23.58
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in and develops real estate assets concentrated in urban infill submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to the legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily and third-party asset management and real estate services. The company generates majority of its revenue from Commercial segment.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.